Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial

Abstract

<b>Background:</b> The efficacy and safety of awake prone positioning&nbsp;(APP) in hypoxemic patients with coronavirus disease 2019 (COVID-19) is unclear. <b>Aim:</b> To evaluate the efficacy and safety of APP in non-intubated adults with COVID-19. <b>Methods:</b> We performed a pragmatic, international, randomized trial at&nbsp;21 centers in Canada, Saudi Arabia, Kuwait, and the United States between May 19, 2020, and May 18, 2021. Eligible patients were hospitalized adults with COVID-19 requiring &gt;40% oxygen.&nbsp;Patients were randomized to&nbsp;APP (n=205) or usual care (n=195).&nbsp;The primary outcome was intubation by day 30. Secondary outcomes included mortality at 60 days, ventilation-free days at 30 days, intensive care unit (ICU) and hospital-free days at 60 days, adverse events, and serious adverse events. <b>Results:</b> Patients in the APP group proned for a median of 4.8 hours per day (IQR 1.8 to 8.0) in the first 4 days. By day 30, 70/205 patients (34.1%) in the&nbsp;APP group and 79/195 (40.5%) in the control group were intubated (hazard ratio [HR] 0.81; 95% confidence interval [CI] 0.59 to 1.12).&nbsp;APP did not reduce mortality at 60 days (HR 0.93; 95% CI 0.62 to 1.40) and had no effect on days alive invasively or noninvasively ventilated at 30 days, or days out of ICU or hospital at 60 days. There were no serious adverse events in either group.&nbsp;A prespecified subgroup analysis suggested that&nbsp;APP reduced intubation among patients with SpO2:FiO2 &gt;150 (HR of 0.44, 95% CI 0.23 to 0.87) but not among patients with SpO2:FiO2 &lt;150 (HR 1.02; 95% CI 0.70 to 1.48; P-interaction= 0.03). <b>Conclusion:</b> APP did not significantly reduce intubation at 30 days or mortality at 60 days overall, but&nbsp;may be effective&nbsp;in patients with&nbsp;SpO2:FiO2 &gt;150.